➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Harvard Business School
Moodys
Merck
Mallinckrodt

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEOMYCIN SULFATE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Neomycin Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00534391 ↗ Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage Unknown status Chulalongkorn University Phase 3 2007-09-01 To compare the effectiveness of combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin) with placebo (artificial tear) in the treatment of hordeolum after incision and curettage
NCT00857688 ↗ Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration Completed Azidus Brasil Phase 3 2011-05-01 To evaluate the efficacy of the product Bismu-Jet ® (bismuth tartrate and sodium, neomycin sulfate and procaine hydrochloride) produced by EMS S / A compared to placebo in reducing the signs and symptoms resulting from UAR in patients of both sexes, with age over 12 years.
NCT01227863 ↗ Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status Azidus Brasil Phase 3 2011-02-01 The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.
NCT02168478 ↗ Neo-Synalar Modified 48 Hour Patch Test Completed Noah Rosenberg, MD Phase 4 2014-06-01 A 48 hour patch test performed in healthy volunteers to determine the presensitization (pre-existing allergy) of Neo-Synalar (neomycin sulfate 0.5%(0.35% neomycin base), fluocinolone acetonide 0.025%) Cream . Subjects also receive a positive control (Sodium Lauryl Sulfate) and a negative control (Saline). The primary objective of this study is to determine if any subjects exhibit an allergic reaction which may be indicative of a pre-existing sensitization.
NCT02472600 ↗ Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy Recruiting European Commission Phase 2 2016-02-01 This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day ) followed by fecal microbiota transplantation (administered either via nasogastric administration or via capsules) is effective at eradicating intestinal carriage of beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult non-immunosuppressed patients .
NCT02472600 ↗ Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy Recruiting Stephen Harbarth Phase 2 2016-02-01 This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day ) followed by fecal microbiota transplantation (administered either via nasogastric administration or via capsules) is effective at eradicating intestinal carriage of beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult non-immunosuppressed patients .
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Neomycin Sulfate

Condition Name

Condition Name for Neomycin Sulfate
Intervention Trials
Bacterial Conjunctivitis 1
Aphtous Ulcers 1
Allergy 1
Tinea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Neomycin Sulfate
Intervention Trials
Infection 1
Signs and Symptoms 1
Conjunctivitis, Bacterial 1
Conjunctivitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Neomycin Sulfate

Trials by Country

Trials by Country for Neomycin Sulfate
Location Trials
United States 2
Brazil 2
Netherlands 1
Israel 1
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Neomycin Sulfate
Location Trials
Georgia 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Neomycin Sulfate

Clinical Trial Phase

Clinical Trial Phase for Neomycin Sulfate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Neomycin Sulfate
Clinical Trial Phase Trials
Unknown status 2
Completed 2
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Neomycin Sulfate

Sponsor Name

Sponsor Name for Neomycin Sulfate
Sponsor Trials
Azidus Brasil 2
Stephen Harbarth 1
European Commission 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Neomycin Sulfate
Sponsor Trials
Industry 4
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.